Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

PURPOSE: Combination treatment with immune checkpoint inhibitors has shown enhanced antitumor activity compared with monotherapy in tumor types such as melanoma. The open-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the efficacy and safety of nivolumab plus ipilimum...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Hammers, Hans J., Plimack, Elizabeth R., Infante, Jeffrey R., Rini, Brian I., McDermott, David F., Lewis, Lionel D., Voss, Martin H., Sharma, Padmanee, Pal, Sumanta K., Razak, Albiruni R. Abdul, Kollmannsberger, Christian, Heng, Daniel Y.C., Spratlin, Jennifer, McHenry, M. Brent, Amin, Asim
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2017
Aiheet:
ORIGINAL REPORTS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7587408/
https://ncbi.nlm.nih.gov/pubmed/28678668
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.72.1985
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia